US FDA public meeting: identification of concepts and terminology for multicomponent biomarkers

Author:

Agyeman Abena S1,Bandukwala Abbas2,Bouri Khaled3,Hawes Jessica4ORCID,Krainak Daniel M5ORCID,Lababidi Samir6ORCID,Mattes William B7ORCID,Mishina Elena V8,Turfle Phillip9ORCID,Wang Sue-Jane10ORCID,Thekkudan Theresa11

Affiliation:

1. Division of Pharmacology & Toxicology–Rare Diseases, Pediatrics, Urologic & Reproductive Medicine, Office of New Drugs (OND), Center for Drug Evaluation & Research (CDER), US FDA, Silver Spring, MD 20993, USA

2. Division of Biomedical Informatics, Research, & Biomarker Development, OND, CDER, FDA, Silver Spring, MD 20993, USA

3. Office of Regulatory Science & Innovation, Office of the Chief Scientist, Office of the Commissioner (OC), FDA, Silver Spring, MD 20993, USA

4. Division of Systems Biology, Office of Research, National Center for Toxicological Research, FDA, Jefferson, AR 72079,

5. Division of Radiological Imaging & Radiation Therapy Devices, Office of Radiological Health, Office of Product Evaluation & Quality, Center for Devices & Radiological Health, FDA, Silver Spring, MD 20993, USA

6. Office of Data, Analytics & Research, Office of Digital Transformation, Office of the Commissioner (OC), FDA, Silver Spring, MD 20993, USA

7. Office of the Center Director, Center for Food Safety & Applied Nutrition (CFSAN), FDA, College Park, MD 20740, USA

8. Division of Individual Health Science, Office of Science, Center for Tobacco Products (CTP), FDA, Beltsville, MD 20705, USA

9. Division of Companion Animal Drugs, Office of New Animal Drug Evaluation, Center for Veterinary Medicine (CVM), FDA, Rockville, MD 20855, USA

10. Division of Biometrics I, Office of Biostatistics, Office of Translational Sciences, CDER, Silver Spring, MD 20993, USA

11. Division of Nonclinical Science, Office of Science, Center for Tobacco Products, FDA, Beltsville, MD 20705, USA

Abstract

The US FDA convened a virtual public workshop with the goals of obtaining feedback on the terminology needed for effective communication of multicomponent biomarkers and discussing the diverse use of biomarkers observed across the FDA and identifying common issues. The workshop included keynote and background presentations addressing the stated goals, followed by a series of case studies highlighting FDA-wide and external experience regarding the use of multicomponent biomarkers, which provided context for panel discussions focused on common themes, challenges and preferred terminology. The final panel discussion integrated the main concepts from the keynote, background presentations and case studies, laying a preliminary foundation to build consensus around the use and terminology of multicomponent biomarkers.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Reference13 articles.

1. US FDA. Identification of concepts and terminology for multi-component biomarkers. www.fda.gov/drugs/news-events-human-drugs/fda-public-meeting-identification-concepts-and-terminology-multi-component-biomarkers-03232022

2. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource (2016). Available from: https://www.ncbi.nlm.nih.gov/books/NBK338448/#IX-S

3. Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3